cMET Dysegulation Advanced Solid Tumors
1 clinical trials · Condition
◉ Watch cMET Dysegulation Advanced Solid Tumors
| Record | Firm | Date |
|---|---|---|
| A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors. (NCT02925104) | Novartis Pharmaceuticals | 2016-12-14 |
Track cMET Dysegulation Advanced Solid Tumors automatically
Every clearance here is in the API, with alerts when new ones post.